← Back to screener

Relay Therapeutics, Inc. RLAY

Rank #2256 · Nasdaq · $3.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
27.1
P/E
-10.3
P/B
3.70
ROE
-36.0%
Op. Margin
-1460.1%
Debt Ratio
10%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -10.3x, P/B 3.70x. Ranks in the top 71% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -36.0%. Ranks in the top 92% of the universe.

Safety ★★★★★
Excellent

Debt ratio 10%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 1749.8% year over year. Ranks in the top 0% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.1B$-0.1B$-0.1B$-0.1B-101.7-32
2021$0.1B$-0.1B$-0.1B$-0.1B-101.7-33
2022$0.1B$-0.1B$-0.1B$-0.2B-67.5-61
2023$0.0B$-0.4B$-0.4B$0.8B-12040.220
2024$0.0B$-0.3B$-0.3B$0.9B-21670.910
2025$0.0B$-0.4B$-0.3B$1.0B-1460.110

← See the full screener